The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.
Rafael Rosell
No relevant relationships to disclose
Miguel Angel Molina-Vila
No relevant relationships to disclose
Miquel Taron
No relevant relationships to disclose
Jordi Bertran-Alamillo
No relevant relationships to disclose
Clara Mayo
No relevant relationships to disclose
Alain Vergnenegre
No relevant relationships to disclose
Filippo De Marinis
No relevant relationships to disclose
Bartomeu Massuti
No relevant relationships to disclose
Javier De Castro
No relevant relationships to disclose
Radj Gervais
No relevant relationships to disclose
Enric Carcereny
No relevant relationships to disclose
Cristina Buges
No relevant relationships to disclose
Teresa Moran
No relevant relationships to disclose
Mariacarmela Santarpia
No relevant relationships to disclose
Enriqueta Felip
No relevant relationships to disclose
Margarita Majem
No relevant relationships to disclose
Joaquim Bosch
No relevant relationships to disclose
Felipe Cardenal
No relevant relationships to disclose
Ana Drozdowskyj
No relevant relationships to disclose
Trever Grant Bivona
No relevant relationships to disclose